TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24273151

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 10 mg/m² once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 40 mg/m² once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 80 mg/m² four times daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine (various doses)
Number of subjects: 23
Study: 24273174

Group type: EXPERIMENTAL
Intervention: MVA85A (in groups B and D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG (in groups A and C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 0
Study: 24273570

Group type: EXPERIMENTAL
Intervention: Newer antiepileptic drugs (AEDs) in monotherapy or combination (24.6% of patients)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Older antiepileptic drugs (AEDs) or combination of older and newer AEDs (75.4% of patients)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Overall treatment modifications
Number of subjects: 309
Study: 24274034

Group type: EXPERIMENTAL
Intervention: Autism (AUT)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Pervasive developmental disorder not otherwise specified (PDD-NOS)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Nonspectrum developmental delays
Number of subjects: 244

Group type: COMPARATOR
Intervention: Typical development (TD)
Number of subjects: 244
Study: 24274658

Group type: EXPERIMENTAL
Intervention: NTM lung disease patients
Number of subjects: 84
Study: 24275120

Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized approach to maintain body iron
Number of subjects: 0
Study: 24275629

Group type: EXPERIMENTAL
Intervention: Reactive hyperemia index (RHI) measured before coronary angiography
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: SYNTAXsc
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: RHI added to FRS, BNP, and SYNTAXsc
Number of subjects: 528
Study: 24275632

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 9974

Group type: COMPARATOR
Intervention: Patient education
Number of subjects: 9974

Group type: COMPARATOR
Intervention: Antiarrhythmic drug use
Number of subjects: 9974
Study: 24275804

Group type: EXPERIMENTAL
Intervention: Structured questionnaire identifying renal dysfunction risk factors (renal disease, renal surgery, hypertension, gout, diabetes)
Number of subjects: 1467

Group type: COMPARATOR
Intervention: No risk factors reported
Number of subjects: 1467

Group type: EXPERIMENTAL
Intervention: Questionnaire for patients <70 years old and eGFR determination for patients >70 years old
Number of subjects: 1467

Group type: EXPERIMENTAL
Intervention: General population referred for CT/MRI
Number of subjects: 1467
Study: 24276017

Group type: COMPARATOR
Intervention: Loss-of-function (LOF) MC4R variants
Number of subjects: 217

Group type: COMPARATOR
Intervention: Gain-of-function (GOF) MC4R variants
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: BDNF SNPs rs12291186 and rs6265
Number of subjects: 217

Group type: COMPARATOR
Intervention: Loss-of-function (LOF) MC4R variants in Hispanic cohort
Number of subjects: 217
Study: 24276047

Group type: EXPERIMENTAL
Intervention: EZN-3042 2.5 mg/kg/dose administered as a single agent on days -5 and -2, then in combination with a 4-drug reinduction chemotherapy on days 8, 15, 22, and 29.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: EZN-3042 2.5 mg/kg/dose (single agent)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of EZN-3042 with intensive reinduction chemotherapy
Number of subjects: 6
Study: 24277073

Group type: EXPERIMENTAL
Intervention: Imatinib (single-agent course following induction)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Imatinib (added to the second phase of induction)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Pre-imatinib standard treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 266
Study: 24277679

Group type: EXPERIMENTAL
Intervention: Intraplatelet (IP) serotonin (5-HT) levels before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraplatelet (IP) serotonin (5-HT) levels
Number of subjects: 60
Study: 24278393

Group type: EXPERIMENTAL
Intervention: Exhaustive exercise test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 week supervised training period (walking/running 4 times per week at 60% heart rate reserve)
Number of subjects: 12
Study: 24278400

Group type: EXPERIMENTAL
Intervention: Azithromycin (1000 mg)
Number of subjects: 59
Study: 24279643

Group type: EXPERIMENTAL
Intervention: Moderate autonomic dysregulation (3<BRS≤6)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Severe autonomic dysregulation (BRS≤3)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Normal BRS (>6)
Number of subjects: 916
Study: 24280543

Group type: EXPERIMENTAL
Intervention: Non-obstructive chronic bronchitis (NCB)
Number of subjects: 597
Study: 24281137

Group type: EXPERIMENTAL
Intervention: Selective A1 Adenosine Receptor Antagonist Rolofylline
Number of subjects: 1962

Group type: EXPERIMENTAL
Intervention: Baseline blood urea nitrogen >35 mg/dL and increase in creatinine >0.1 mg/dL per day
Number of subjects: 1962

Group type: EXPERIMENTAL
Intervention: Stable or decreasing creatinine
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1962
Study: 24281330

Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 8583
Study: 24282221

Group type: EXPERIMENTAL
Intervention: RAPD score assessment using an automated pupillometer
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined structure function index (CSFI)
Number of subjects: 103

Group type: COMPARATOR
Intervention: RAPD score > 0.3
Number of subjects: 103
Study: 24282247

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise programme (26 weeks)
Number of subjects: 97
Study: 24282248

Group type: EXPERIMENTAL
Intervention: letrozole and berberine
Number of subjects: 660

Group type: COMPARATOR
Intervention: letrozole and berberine placebo
Number of subjects: 660

Group type: COMPARATOR
Intervention: letrozole placebo and berberine
Number of subjects: 660
Study: 24282249

Group type: EXPERIMENTAL
Intervention: Sexual rehabilitation programme plus usual care
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 154
Study: 24282316

Group type: EXPERIMENTAL
Intervention: Physical activity (measured by steps per day and time spent in vigorous physical activity)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sedentary behaviors
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 95
Study: 24283202

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg BID, with potential increase to 10 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg BID
Number of subjects: 0
Study: 24283216

Group type: EXPERIMENTAL
Intervention: DRD2 genotype (rs18000497 T-alleles)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (OBELDICKS)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Cross-sectional comparison with lean adult controls
Number of subjects: 451
Study: 24284293

Group type: EXPERIMENTAL
Intervention: CLEAR regimen (Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin)
Number of subjects: 15
Study: 24284413

Group type: EXPERIMENTAL
Intervention: HAV vaccination (0 and 6 to 12 months)
Number of subjects: 419

Group type: COMPARATOR
Intervention: HAV vaccination in patients treated with anti-TNF monoclonal antibody infliximab or adalimumab
Number of subjects: 419

Group type: COMPARATOR
Intervention: HAV vaccination in patients not treated with anti-TNF agents
Number of subjects: 419

Group type: COMPARATOR
Intervention: HAV vaccination in patients treated with ≥2 immunosuppressants
Number of subjects: 419

Group type: COMPARATOR
Intervention: HAV vaccination in patients treated with <2 immunosuppressants
Number of subjects: 419

Group type: COMPARATOR
Intervention: HAV vaccination comparing anti-TNF alone with anti-TNF and other immunosuppressants
Number of subjects: 419

Group type: COMPARATOR
Intervention: HAV vaccination in patients receiving anti-TNF therapy
Number of subjects: 419
Study: 24284865

Group type: EXPERIMENTAL
Intervention: Chimpanzee adenovirus-MVA immunisation
Number of subjects: 14
Study: 24284925

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24285015

Group type: EXPERIMENTAL
Intervention: Doxorubicin HCl liposome injection (DLI) 20 mg/m(2) i.v. every 2 weeks for 16 weeks (8 doses) followed by Bexarotene 300 mg/m(2) orally for 16 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bexarotene 300 mg/m(2) orally for 16 weeks
Number of subjects: 37
Study: 24285681

Group type: EXPERIMENTAL
Intervention: Follicular fluid (FF) estradiol levels in AAW
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Follicular fluid (FF) estrone levels in AAW
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: FF androstenedione to estrone ratio in AAW
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: FF testosterone to estradiol ratio in AAW
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Granulosa cell aromatase mRNA expression in AAW
Number of subjects: 29

Group type: COMPARATOR
Intervention: FSH, inhibin A, inhibin B, and AMH levels
Number of subjects: 29
Study: 24286269

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 88
Study: 24287082

Group type: EXPERIMENTAL
Intervention: Bone Marrow Mononuclear Cells (BMMC) infusion
Number of subjects: 0
Study: 24287594

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (non-exposed to CBZ)
Number of subjects: 400
Study: 24287733

Group type: EXPERIMENTAL
Intervention: Viral warts
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Drug-related skin disorders
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pre-malignant and malignant skin disorders
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bacterial and fungal infections
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cumulative incidences of skin disorders
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prevalence data of skin disorders
Number of subjects: 70
Study: 24288021

Group type: EXPERIMENTAL
Intervention: Social network size and type, perceived emotional support
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Instrumental support seeking
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Instrumental support seeking with interdependent self-construal
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Less interdependent self-construal with more instrumental support
Number of subjects: 150
Study: 24288556

Group type: EXPERIMENTAL
Intervention: Individualized acupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standardized acupuncture
Number of subjects: 150
Study: 24289141

Group type: EXPERIMENTAL
Intervention: Oral paliperidone extended-release (ER) 3 to 12 mg daily for 26 to 52 weeks
Number of subjects: 213
Study: 24289658

Group type: EXPERIMENTAL
Intervention: TIV/10 (seasonal trivalent inactivated vaccine 2010)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine
Number of subjects: 60
Study: 24289796

Group type: EXPERIMENTAL
Intervention: Oxytocin administration during labor
Number of subjects: 316
Study: 24290461

Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy with family-focused behavioral intervention
Number of subjects: 160
Study: 24290615

Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter (SAD)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 740
Study: 24290800

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes (abnormal hemisphere)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes (normal hemisphere)
Number of subjects: 30
Study: 24291224

Group type: EXPERIMENTAL
Intervention: GH stimulation testing with GHRH-arginine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Peak stimulated GH
Number of subjects: 138
Study: 24291380

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI) therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 35
Study: 24291783

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable everolimus-eluting vascular scaffold
Number of subjects: 101
Study: 24292639

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 207

Group type: COMPARATOR
Intervention: MetS+ individuals
Number of subjects: 207
Study: 24292957

Group type: EXPERIMENTAL
Intervention: Apatinib 750 or 500 mg/day orally in 4-week cycles
Number of subjects: 80
Study: 24293774

Group type: EXPERIMENTAL
Intervention: Depot GnRHa (leuprolide 3.75-mg)
Number of subjects: 29
Study: 24294924

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 ug/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Chronic cough patients
Number of subjects: 43
Study: 24295096

Group type: EXPERIMENTAL
Intervention: Interventions for depression in hospice caregivers, specific interventions not detailed.
Number of subjects: 0
Study: 24295437

Group type: EXPERIMENTAL
Intervention: Histrelin implant (50-mg subcutaneous annually)
Number of subjects: 36
Study: 24295572

Group type: EXPERIMENTAL
Intervention: Vorinostat (100 mg or 200 mg, twice a day) initiated 10 days before haemopoietic stem-cell transplantation until day 100, in combination with standard immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28) and tacrolimus (0.03 mg/kg a day, titrated to a goal level of 8-12 ng/mL, starting day -3 until day 180)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard immunoprophylaxis of mycophenolate mofetil and tacrolimus
Number of subjects: 50
Study: 24295986

Group type: EXPERIMENTAL
Intervention: Danoprevir-ritonavir (DNVr) plus peginterferon alfa-2a-ribavirin for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Danoprevir-ritonavir (DNVr) plus peginterferon alfa-2a-ribavirin
Number of subjects: 24
Study: 24296492

Group type: EXPERIMENTAL
Intervention: Novel reduced-intensity conditioning (RIC) regimen consisting of hydroxyurea, alemtuzumab, fludarabine, melphalan, and thiotepa followed by single umbilical cord blood transplantation (UCBT).
Number of subjects: 22
Study: 24296713

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral glucose stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control groups (severely obese normal glucose-tolerant and lean)
Number of subjects: 34
Study: 24297161

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 15
Study: 24297771

Group type: EXPERIMENTAL
Intervention: Late PCI with optimal medical therapy (OMT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Late PCI with OMT
Number of subjects: 43
Study: 24297953

Group type: EXPERIMENTAL
Intervention: Fractionated (90)Y-ibritumomab tiuxetan (90Y-IT) administered in two doses of 11.1 MBq/kg, 8 to 12 weeks apart.
Number of subjects: 74
Study: 24298176

Group type: EXPERIMENTAL
Intervention: Thrombolysis administered within 90 minutes of ictus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolysis service
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct intra-arterial intervention such as thrombectomy
Number of subjects: 0
Study: 24298851

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24300167

Group type: EXPERIMENTAL
Intervention: Q wave area
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Selvester QRS-score
Number of subjects: 158
Study: 24300594

Group type: EXPERIMENTAL
Intervention: PPV23/PCV13 (n=50)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PCV9/PCV13 (n=39)
Number of subjects: 89

Group type: COMPARATOR
Intervention: PPV23/PCV13
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PCV9/PCV13
Number of subjects: 89
Study: 24303954

Group type: EXPERIMENTAL
Intervention: GCF biomarkers (MMP-8, MMP-9, Osteoprotegerin, C-reactive Protein, IL-1β)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of biofilm pathogens and GCF biomarkers with clinical measures
Number of subjects: 100
Study: 24304125

Group type: EXPERIMENTAL
Intervention: Vitiligo
Number of subjects: 350
Study: 24304654

Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with invasive DBP and MBP
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with oscillometric brachial SBP and DBP
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with DBP and MBP (ff = 0.33)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SphygmoCor device calibrated with DBP and MBP (ff = 0.40)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Calibration with average of 3 brachial BPs
Number of subjects: 34
Study: 24304924

Group type: EXPERIMENTAL
Intervention: Foods with added fiber (23 g/d)
Number of subjects: 15
Study: 24305645

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 20
Study: 24305979

Group type: EXPERIMENTAL
Intervention: Reporting of arthralgia/myalgia/carpal tunnel (AMC) symptoms
Number of subjects: 4798

Group type: EXPERIMENTAL
Intervention: Reporting of vasomotor symptoms
Number of subjects: 4798
Study: 24307008

Group type: EXPERIMENTAL
Intervention: Young smokers
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy nonsmokers
Number of subjects: 72
Study: 24307220

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (SH)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Lanthanum carbonate (LC)
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (SH) to Lanthanum carbonate (LC) conversion
Number of subjects: 691
Study: 24307472

Group type: EXPERIMENTAL
Intervention: Survey assessing constructs from theoretical frameworks including fear appeal theories
Number of subjects: 481
Study: 24307695

Group type: EXPERIMENTAL
Intervention: High-throughput sequencing (HTS) of T cell receptors (TCRB)
Number of subjects: 10
Study: 24307992

Group type: EXPERIMENTAL
Intervention: Automated diagnostic test using NMR spectrum of urine samples
Number of subjects: 988
Study: 24308791

Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tivantinib
Number of subjects: 0
Study: 24308871

Group type: EXPERIMENTAL
Intervention: Lactose ingestion in IBS-D patients with lactose intolerance (LI)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lactose ingestion in IBS-D patients with LI
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Severity of abdominal symptoms after lactose ingestion
Number of subjects: 55
Study: 24309189

Group type: EXPERIMENTAL
Intervention: eGFR(Cr+Cys)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: eGFR(Cr)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: eGFR(Cys)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: BP and hemoglobin A1c
Number of subjects: 1441
Study: 24309199

Group type: EXPERIMENTAL
Intervention: Open-source based data-sharing infrastructure
Number of subjects: 0
Study: 24309956

Group type: EXPERIMENTAL
Intervention: Serial measurement of IGFBP7
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Rising mimecan levels
Number of subjects: 142
Study: 24309981

Group type: EXPERIMENTAL
Intervention: Chemoradiation and cediranib
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemoradiation only (Control)
Number of subjects: 40
Study: 24311016

Group type: EXPERIMENTAL
Intervention: Verbal reassurance by dental staff
Number of subjects: 270

Group type: COMPARATOR
Intervention: No verbal reassurance (implied control)
Number of subjects: 270
Study: 24311231

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography (DCE-CT)
Number of subjects: 23
Study: 24311296

Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 80
Study: 24311480

Group type: EXPERIMENTAL
Intervention: High food reinforcement (PMAXHED)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Low food reinforcement (PMAXLED)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Low delay discounting (DD)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: High delay discounting (DD10 and DD100)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Interaction of PMAXLED × DD10
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Interaction of PMAXHED × DD10
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Interaction of PMAXHED × DD100
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Interaction of PMAXLED × DD100
Number of subjects: 199
Study: 24311637

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg starting dose, maintenance dose between 12.5 mg and 50 mg depending on tolerability
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sunitinib treatment
Number of subjects: 40
Study: 24311704

Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 concentrations
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 levels
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Serum phosphorus levels
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Serum 1,25-dihyroxyvitamin D concentrations
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Secondary hyperparathyroidism
Number of subjects: 464
Study: 24311743

Group type: EXPERIMENTAL
Intervention: Training rehabilitation professionals in communication and motivation skills
Number of subjects: 0
Study: 24313609

Group type: EXPERIMENTAL
Intervention: Authors' analysis of risk factors for cranial CT necessity
Number of subjects: 12876

Group type: COMPARATOR
Intervention: Canadian CT Head Rule (CCHR)
Number of subjects: 12876